Skip to main content

Mycotoxin exposure is associated with increased risk of esophageal squamous cell carcinoma in Huaian area, China

Abstract

Background

Consumption of moldy food has previously been identified as a risk factor for esophageal squamous cell carcinoma (ESCC) in high-risk countries; however, what contributing roles these dietary carcinogenic mycotoxins play in the etiology of ESCC are largely unknown.

Methods

A mycotoxin biomarker-incorporated, population-based case-control study was performed in Huaian area, Jiangsu Province, one of the two high-risk areas in China. Exposure biomarkers of aflatoxins (AF) and fumonisins (FN) were quantitatively analyzed using HPLC-fluorescence techniques.

Results

Among the cases (n = 190), the median levels of AF biomarker, serum AFB1-lysine adduct, and FN biomarker, urinary FB1, were 1.77 pg/mg albumin and 176.13 pg/mg creatinine, respectively. Among the controls (n = 380), the median levels of AFB1-lysine adduct and urinary FB1 were 1.49 pg/mg albumin and 56.92 pg/mg creatinine, respectively. These mycotoxin exposure biomarker levels were significantly higher in cases as compared to controls (p <  0.05 and 0.01, respectively). An increased risk to ESCC was associated with exposure to both AFB1 and FB1 (p <  0.001 for both).

Conclusions

Mycotoxin exposure, especially to AFB1 and FB1, was associated with the risk of ESCC, and a greater-than-additive interaction between co-exposures to these two mycotoxins may contribute to the increased risk of ESCC in Huaian area, China.

Peer Review reports

Background

Esophageal cancer is one of the most common cancers worldwide, ranked 7th in incidence in males, 6th and 9th in cancer-related death in males and females worldwide, respectively [1], and considerably higher in both incidence and cancer-related death in many developing countries [1,2,3]. The highest incidences of esophageal cancer were found in East and Southern Africa, Northern France, and Central Asia, with the notorious “Central Asia esophageal cancer belt” extending from northeastern China westward to northern Iran along the Silk Road, spanning several countries including China, Turkmenistan, Uzbekistan, Karakalpakstan, Kazakhstan, and Iran [2,3,4]. There are two main types of esophageal cancers, namely, the squamous cell carcinoma (ESCC), and adenocarcinoma (EAC). ESCC constitutes of majority of esophageal cancer cases, and was more prevalent with high incidences in developing nations such as China, with the primary risk factor being dietary patterns and environmental factors, as well as individual genetic predispositions [1, 5]. Whereas for EAC, the rates are increasing in the US and other developed nations in past decades, and the risks were postulated to be linked to obesity, as well as various preexisting conditions, such as Barrett’s esophagus and reflux symptoms [6].

Consumption of moldy and mycotoxin-contaminated food has previously been identified as a risk factor for ESCC in high-risk countries [5, 7, 8]; however, what contributing roles thesedietary carcinogenic mycotoxins play in the etiology of ESCC are largely unknown. Aflatoxin B1 (AFB1) and fumonisin B1 (FB1) are among the most well-known mycotoxins found in commonly consumed foods and feed products [9]. AFB1, a Group 1 human carcinogen and a representative of the aflatoxin family, is produced by fungal contaminants, Aspergillus flavus and A. parasiticus [10]. It is considered to be a major food contaminant worldwide, affecting food and products of, including but not limited to, corn, peanuts, milo, sorghum, copra, and rice [11]. FB1, on the other hand, is a Group 2B carcinogen and a representative of fumonisin family, produced primarily by maize pathogens, Fusarium verticillioides and F. proliferatum, which contaminates maize and maize-based products ubiquitously [12, 13]. As both Aspergillus and Fusarium can contaminate and often co-exist on maize and some other cereal grains, concerns for human co-exposure to these two mycotoxins, and its consequences, have been raised [14, 15]. Co-existence of AFB1 and FB1 in food items has already been reported in several studies worldwide, particularly from Asia, South and Central America, and Africa [16,17,18,19,20,21]. Consequently, efforts must now be made to assess the extent of human co-exposure to these mycotoxins, as well as the adverse health effects they may have, in order to more accurately assess the risk posed by the nature of co-contamination and co-exposure [22].

Dietary FB1 exposure has been proposed as one of the major environmental factors associated with increased risk of ESCC in developing countries [23]. The first association between FB1 and human esophageal cancer was proposed by Sydenham el al., who reported FB1 contamination in the Transkei region, a high incidence area of esophageal cancer in Africa [7, 23]. In Huaian, China, another high-risk area for ESCC, FB1 was detected in 95.7% (112/117) of corn samples, with an average of 2.84 mg/kg (range: 0.1–25.5 mg/kg) [24]. Co-contamination of FB1 with other mycotoxins, particularly AFB1, has also been reported in this high ESCC risk area. In Huaian area, the mean level of AFB1 in food was estimated to be 13.5 μg/kg, with estimated daily intake of 1.723 μg (range 0.224–49.772 μg) [19]. Similarly, in high risk areas of Cixian and Linxian counties, China, co-contamination of AFB1 and FB1 were detected at mean levels of 8.61 μg/kg (range: 1–38.4 μg/kg) and 35.3 mg/kg (range: 20–60 mg/kg), respectively [8].

The use of molecular biomarkers, facilitated by understanding of toxicokinetics and toxicodynamics of environmental toxicants, has improved the assessment of individual exposure beyond the levels detected in external media, such as in food, as well as estimations based on questionnaires [25]. For AFB1, the most widely acceptable exposure biomarker is serum AFB1-lysine adducts, formed by covalently binding of AFB1-diol with lysine residue on serum albumin [11]. It is reasonably stable in blood until albumin turnover, thus making the levels of this adduct highly reflective of chronic exposure [11]. This adduct has been validated and utilized as a reliable indicator of chronic exposure in both animal and human epidemiological studies [11, 26]. For FB1, the orally dosed toxin is poorly absorbed and rapidly eliminated with no major metabolites produced in humans; nonetheless, the parent compound can be measured directly in biological fluids, such as urine, as a biomarker of FB1 exposure, which has also been validated in human population studies [27,28,29,30,31].

Dietary exposure to mycotoxins has been linked to the etiology of several gastrointestinal cancer sites and chronic diseases in many developing countries [7, 9, 32, 33]. The co-contamination of AFs and FNs in human diets has been widely reported, and epidemiological studies have indicated the potential contributory effect of the two mycotoxins in etiologies of human liver and esophageal cancer [19, 20, 34, 35]. Combinative exposure to the two mycotoxins often showed greater toxic effects, and potentially synergistic effects on tumorigenesis, in animal and human cell models, when compared to either AFB1 or FB1 alone [36,37,38]. To better understand the contributing roles and mechanisms these exposures have in human esophageal carcinogenesis, we used biomarker approach to evaluate their contributing risk of ESCC, specifically, serum AFB1-lysine and urinary FB1. Furthermore, we examined potential interactions, including additive effects, between mycotoxin exposures and increased risk of ESCC in Huaian, China.

Methods

Chemicals and reagents

AFB1-lysine adduct standard was synthesized and purified as previously described by Sabbioni et al. [39]. Albumin determination reagent (bromocreosol purple), and normal human serum were purchased from Sigma Aldrich Chemical Co. (St. Louis, MO). Pronase (25 kU, Nuclease-free) was purchased from Calbiochem (La Jolla, CA). Protein assay dye reagent concentrate and protein standards were purchased from Bio-Rad Laboratories Inc. (Hercules, CA). Boric acid, o-phthaldialdehyde (OPA), 2-mercaptoethanol, FB1 from F. verticilioides (~ 98% purity, TLC), 10× phosphate buffered saline (PBS), ammonium hydroxide, ammonium acetate, sodium chloride, sodium phosphate monobasic, hydrochloric acid, and formic acid were purchased from Sigma-Aldrich (St. Louis, MO, USA). OPA reagents were prepared by dissolving 10 mg of OPA and 30 μl of 2-mercaptoethanol in 250 μl of methanol and mixing with 4.75 ml of 3% boric acid buffer (pH 10.5) and stored at 4 °C avoiding light before use. Mixed mode solid phase extraction (SPE) cartridges, as well as Sep-Pak reversed phase C18 cartridges were purchased from the Waters Corp. (Milford, MA). All other chemicals and solvents were of highest grade and purity available.

Study site and populations

Huaian area, located in the northern area of Jiangsu Province of China, is one of the two endemic areas for esophageal cancers in China (the other being the southern Taihang Mountain area, including Linzhou of Henan Province and Cixian of Hebei Province), with incidence over 80 per 100,000, six times greater than the national average rate [5]. The study followed a population-based case-control design, with the participants recruited from five rural farming communities (townships) belonging to the Huaian District. The location of the study site is shown in Fig. 1. Cases consist of ESCC diagnosed in 2006–2007 from the malignant tumor registration record, and healthy controls were matched by age, gender, and residency. After signed written consent, a face-to-face interview was conducted, and a total of 190 cases and 380 controls were recruited. Questionnaire on demographics [5, 40], disease history and dietary pattern, blood sample (5 mL), and the morning urine sample (50 mL) were collected. Personnel conducting laboratory analyses were blinded to case and control status. The study protocols including ethics guideline and consent form were approved by the Institutional Review Boards for human subjects at Southeast University School of Public Health and Texas Tech University (human subject assurance number: 00001568) and was compliant with human research guidelines of the respective institutions.

Fig. 1
figure1

Map of Huaian area, Jiangsu Province, China. Circled with arrow indicate the townships where the study participants were recruited for this case-control study. Map of Huaian was traced using Adobe Photoshop CS2 (https://www.adobe.com/), with texts and indicators added with Microsoft PowerPoint (https://www.microsoft.com/en-us/). No copyright issue present

HPLC-FLD analysis of serum AFB1-lysine adduct

Overall sample processing used a method previously reported in Qian et al. 2013 [41]. Briefly, thawed human serum samples underwent pathogen deactivation via submerging sample tubes in 56 °C water bath for 30 min. Serum albumin and total protein were analyzed with respective reagents, as described previously. An aliquot of 150 μl serum was then digested via pronase (1:4 pronase:total protein, w:w), in 37 °C water bath for 3 h to optimize the conditions of enzyme digestion in order to release lysine adducts. The contents were then purified via solid phase extraction, using Waters MAX SPE cartridges over vacuum chamber manifold. Samples were eluted with 2% formic acid in methanol, vacuum-dried with a Labconco Centrivap concentrator, and reconstituted with 150 μl of 25% methanol prior to injection.

AFB1-lysine adduct was quantified using Agilent 1100 HPLC-fluorescence detection system (Agilent Technologies, Wilmington, DE, USA), at excitation/emission of 405/470 nm. Chromatographic separations were achieved using Zorbax Eclipse XDB-C18 reverse phase column (5 μm, 4.6 × 250 mm), with a gradient of 20 mM NH4H2PO4, pH 7.2 (Buffer A), and 100% methanol (Buffer B), to achieve separation within 25 min at flow rate of 1.0 ml/min. For each injection, 100 μl of processed samples were used. Final concentrations were obtained via manual integration and calculation using a standard curve, then adjusted by albumin content of corresponding samples, to obtain the exposure parameters in units of pg/mg albumin. The limit of detection for the method used is 0.4 pg AFB1-lysine /mg albumin.

Measurement of urinary Creatinine

Creatinine concentration in urine samples was analyzed using the 96-well Creatinine Assay Kit from Cayman Chemical (Ann Arbor, MI, USA). The analysis is based on a modified Jaffe colorimetric method that measures the difference in absorbance (495 nm) of the creatinine-picrate complex before and after acidification. The assay was carried out according to manufacturer’s instructions, and absorbance was measured using an ELx808 Absorbance Microplate Reader from BioTek Instruments, Inc. (Winooski, VT, USA).

HPLC-FLD analysis of urinary FB1

Urinary FB1 was analyzed based on previous studies [42]. Briefly, 10 ml aliquot of urine samples were centrifuged to remove pellets. The supernatant was passed through FumoniTest column by gravity. After washing with 10 mL 1x PBS, FB1 was eluted three times with 0.5 mL of 20% methanol in 10 mM hydrochloric acid directly onto pre-conditioned Waters Oasis HLB cartridge and sequentially washed with HPLC grade water and 25% methanol, three times each. The contents were then eluted with 2% formic acid in methanol and dried under a gentle stream of nitrogen gas while incubated in 35 °C water bath. Dried residues were then reconstituted with 200 μl 50% methanol, and 150 μl were transferred to injection vial for analysis.

HPLC analysis was performed with Agilent 1100 HPLC-fluorescence detection system. On-line derivatization of analytes with OPA reagent was performed via injection program, which mixes 10 μl of reagent with sample for 1 min prior to injection. The injection volume was 100 ul. Chromatographic separation achieved Zorbax Eclipse XDB-C18 reverse phase column (5 μm, 4.6 × 250 mm) maintained at 35 °C. The mobile phases consist of 0.1 M sodium phosphate monobasic (pH 3.4) (Buffer A) and methanol (Buffer B). The flow rate of mobile phase was 1.0 mL/min, consisting of linear gradient starting from Buffer A: Buffer B (35:65, v/v) to Buffer A: Buffer B (20:80, v/v) over 13 min. OPA derivatives of FB1 were monitored at excitation/emission of 300/ 440 nm. The limit of quantitation was 20 pg per injection. The measured urinary FB1 levels were adjusted by creatinine concentration of corresponding urine samples to obtain the exposure parameters in units of pg/mg creatinine.

Statistical analysis

Descriptive statistics, including mean ± SD, median, and range (or distribution quadrants), were calculated for each exposure parameter. Detailed epidemiological questionnaire data, including tobacco, alcohol consumption, dietary pattern, etc., were assessed as well. The association between exposure parameters with the risk of ESCC was estimated by conditional logistic regression model. Odds ratios (ORs) and their 95% confidence interval (CI) for ESCC risk were calculated. The interaction of mycotoxins was estimated by using crossover analysis. Interaction parameters, including relative excess risk due to interaction, proportion attributable to interaction, and synergy index, were calculated using methods described by Andersson et al. [43]. All statistical tests were two-sided, with p-value of < 0.05 considered statistically significant. All analyses were conducted in SAS 9.4 (SAS Institute, Cary, NC, USA).

Results

Population characteristics

Demographic information is summarized in Table 1. There were no significant differences between cases and controls in cumulative alcohol and tobacco uses. Significant differences were found between cases and controls in education attainment, as well as individual income per month at the time of recruitment and 10 years before the recruitment.

Table 1 Demographic and socioeconomic characteristics of cases and matched controls

Mycotoxins exposure and ESCC risks

Urinary free FB1 was detectable in 95.8% (181/189) of the ESCC cases and 84.2% (319/379) of the controls, and serum AFB1-lysine was detectable in 90.7% (146/161) of the cases and 69.3% (142/205) of the controls. The mean, median, standard deviation, and quartiles for AFB1-lysine as well as urinary FB1 for both cases and controls are summarized in Table 2 and Fig. 2. Both urinary free FB1 (Fig. 2a) and serum AFB1-lysine (Fig. 2b) levels were significantly higher in cases than in controls (p <  0.01 and <  0.05, respectively).

Table 2 Serum AFB1-lysine and Urinary FB1 levels of Huaian Esophageal Cancer Case and Control samples
Fig. 2
figure2

Comparison of biomarker levels between cases and controls. Plots depict overall levels of a urinary FB1 and b serum AFB1-lysine adducts in esophageal cancer case and control samples. Boxes in the plot represent 25 and 75 percentiles, with the medians as the middle lines. Bars represent 5 and 95 percentiles of data

Table 3 shows the ESCC risks associated with exposure to FB1 and AFB1. Continuous variables were converted into binary categorical variables based on the population median for urinary FB1 and serum AFB1 in control groups, thereby dividing the populations into low- and high- exposure groups. For both urinary FB1 and AFB1, high exposure groups have significantly higher odds ratios for ESCC (p <  0.001 for all), with greater percentage of cases categorized as high exposure for both FB1 and AFB1 (Table 4).

Table 3 ESCC risk and urinary free FB1 and serum AFB1-lysine levels
Table 4 Interaction of FB1 and AFB1 exposure on risk of esophageal cancer

Interaction between two mycotoxins exposures

Evaluation of interaction between FB1 and AFB1 exposure on ESCC risks is summarized in Table 4. The risk for high levels of exposure to both FB1 and AFB1 is significantly higher than that of either high FB1 or high AFB1 alone. The combination of high exposure to both FB1 and AFB1 resulted in positive interaction, indicating a potentially greater-than-additive risk with co-exposure of FB1 and AFB1 in affecting ESCC risks.

Discussion

In the present study, we assessed the exposure to potent mycotoxins, AFB1 and FB1, using corresponding exposure biomarkers and evaluated their associations with the risk for ESCC in Huaian area, China. We evaluated risk associated with individual factors, as well as binary interaction between factors based on logistic regression. Based on the results, high level exposure to AFB1 and FB1 were associated with increased risk to ESCC, and greater-than-additive interaction exists between high AFB1 and FB1 exposure. The overall dietary patterns and staple food have not been changed for decades in the study area and populations [5, 19, 40], despite of possible periodic variations; therefore, measurement for biomarker levels are reflective of both the current and past exposures, which might be even higher than the currently measured exposure levels.

Previous studies have confirmed the association between FN exposure and ESCC risks, with the earliest association between ESCC and FN was established in the Transkei region of southern Africa, an international esophageal cancer hot spot [7, 44]. Studies have found significantly higher levels of Fusarium verticillioides infection and FB1 and B2 levels in homegrown corn samples collected from higher-risk areas compared to those from lower-risk areas [45,46,47,48]. Various populations within the region were also found to have exposure levels exceeding the recommended provisional maximum tolerable daily intake of 2 μg/kg bw [46, 47, 49]. In China, a survey of 282 corn samples from 6 provinces found detectable FB1 in 99.6% samples, with 25.2% of samples having levels higher than 5 mg/kg [50]. In high risk counties of Cixian and Linxian (now Linzhou), FB1 has been detected in all corn samples collected from local households, where half of the samples, with heavy mold contamination, have a mean FB1 level of 74 mg/kg (range: 18–155 mg/kg), while the other half, without visible mold contamination, showed an average FB1 level of 35.3 mg/kg (range: 20–60 mg/kg) [8]. However, a biomarkers-based study found no association of sphingosine, sphinganine, and sphinganine/sphingosine ratios with ESCC [51], though later studies suggested that sphingolipid levels may not be sensitive biomarkers for exposure in human populations [48, 49]. Although these studies suggested the potential role of FB1 exposure in esophageal cancer development, confirmations of FB1 exposure in human disease risks with validated exposure biomarkers have not been studied and published.

While AFs are more commonly associated with risk for hepatocellular carcinoma (HCC) [9], evidences have suggested their potential link to the risk of ESCC. Co-contamination of AFs with FNs has been reported in high-risk areas of ESCC in China, including Cixian and Linxian (now Linzhou), as well as Huaian regions [8, 19]. The association between AFs contamination and risks of esophageal cancer was further demonstrated by a study in Golestan province of Iran, where the total AFs levels in wheat flour samples was significantly higher in high-risk areas compared to low-risk areas [52]. The current study, which detected exposure to AFB1 via serum exposure biomarkers, confirms the co-contamination of AFB1 with FB1 in the high-risk area, as well as the association of high AFB1 exposure with ESCC risk. Furthermore, the current study found a greater-than-additive interaction between AFB1 and FB1 exposure via both binary interaction assay and higher-order analysis. It should be noted, however, that our study found marginal significance (p = 0.06) in terms of association of ESCC with low FB1-high AFB1 exposures. This may be due to the lack of sufficient participant numbers recruited in our study (n) to delineate the higher significance. On the other hand, the role of AFB1 exposure in contributing risks of cancers other than liver, such as lung, colorectal and esophagus, have been rarely examined [53, 54]. While the association between food AFB1 contamination and ESCC has been reported, there is a very high likelihood that co-contaminations of AFB1 with FB1 or other mycotoxins is also present in the study areas [33, 52]. While the potential mechanisms of AFB1 in ESCC risk remain to be elucidated, in an in vitro study, AFG1, a less toxic variant of AFs, is shown to reduce the expression of HLA-I, TAP-1, and LMP-2, critical components in antigen presentation and antigen processing, in adult esophageal epithelial cells, which can ultimately lead to defect in antigen presentation to T-lymphocytes, potentiating tumorigenesis via escaped immune surveillance, therefore potentially linking AF exposure to esophageal cancer [55].

Studies have demonstrated that the co-contamination of AFs and FNs, and the potential interaction of the two, may play a great role in etiology of many mycotoxin-related diseases and health outcomes. Epidemiological studies have pin-pointed the potential contributory effect of FB1 on HCC linked to AFB1 exposure, with co-contamination of AFB1 and FB1 detected in several areas with historically high risks for HCC, including parts of Guatemala and China [19, 20, 34, 35]. Using molecular biomarkers of exposure, Shirima et al. found chronical co-exposure to both AF and FN among young Tanzanian children via contaminated diet, and the levels were negatively associated with growth parameters, implying contribution to growth impairments [56, 57]. At the same time, in animal and model organism studies, combinations of the two mycotoxins often showed greater toxic effects when compared to either AFB1 or FB1 alone, with some studies pointing to a clear additive effect on toxicity, and others showing potentially synergistic effects on tumorigenesis; for example, FB1 was shown to promote AFB1-initiated liver tumor in rainbow trout and development of pre-neoplastic liver lesions in F344 rats [36,37,38]. The mechanisms of toxicity suggest that, while FB1 does not act as direct carcinogen like AFB1, it can be a potent promoter of AFB1-induced tumorigenesis, as FB1 can significantly alter sphingolipid profile in both animals and humans by inhibiting ceramide synthase, which can further affect apoptosis and potentially other signaling pathways [37, 38, 58,59,60,61]. Although further studies are required to fully elucidate the interaction between AFB1 and FB1 in human and animal carcinogenesis and other adverse health effects, it is clear that analysis of single mycotoxin may not be sufficient in assessment of potential cancer risks, and the setting of regulatory standards, which were established based on individual toxicant or carcinogen, may not necessarily be protective enough when considering the combinative effect of mycotoxins.

As shown in Table 1, we did not find significant association of ESCC cases with alcohol consumption and smoking status in the current study, which is consistent with many previously published studies in China, including studies for liver cancer, as well as studies conducted in the same area for esophageal cancer [5, 40, 62, 63]. The major reasons for lack of such association are the prevalence of alcohol drinking (nearly 100% in the study participants) and the nature of the matched case-control design. The same would apply for the lack of association for smoking status, with almost 100% study participants are active (males) or secondhand (females) smokers. The limitation of this study includes the nature of case-control study design, which can’t reveal a causative correlation, but only show associations.

Conclusions

Mycotoxin exposure, especially to AFB1 and FB1, was associated with the risk of ESCC, and a greater-than-additive interaction between co-exposures to these two mycotoxins may contribute to the increased risk of ESCC in the studied population in Huaian area, China.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the request to the corresponding author.

Abbreviations

AFB1 :

Aflatoxin B1

EAC:

Adenocarcinoma

ESCC:

Esophageal squamous cell carcinoma

FB1 :

Fumonisin B1

HCC:

Hepatocellular carcinoma

References

  1. 1.

    American Cancer Society. Global Cancer Facts & Figures. 3rd ed. Atlanta: American Cancer Society; 2015.

    Google Scholar 

  2. 2.

    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

    Article  Google Scholar 

  3. 3.

    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.

    Article  PubMed  Google Scholar 

  4. 4.

    Kamangar F, Malekzadeh R, Dawsey SM, Saidi F. Esophageal cancer in northeastern Iran: a review. Arch Iran Med. 2007;10(1):70–82.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Wang Z, Tang L, Sun G, Tang Y, Xie Y, Wang S, et al. Etiological study of esophageal squamous cell carcinoma in an endemic region: a population-based case control study in Huaian, China. BMC Cancer. 2006;6:287.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol. 2013;19(34):5598–606.

    Article  PubMed  PubMed Central  Google Scholar 

  7. 7.

    Marasas WF. Discovery and occurrence of the fumonisins: a historical perspective. Environ Health Perspect. 2001;109(Suppl 2):239–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Chu FS, Li GY. Simultaneous occurrence of fumonisin B1 and other mycotoxins in moldy corn collected from the People's Republic of China in regions with high incidences of esophageal cancer. Appl Environ Microbiol. 1994;60(3):847–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. 9.

    IARC. In: Wild CP, Miller JD, Groopman JD, editors. Mycotoxin control in low- and middle- income countries. Lyon: WHO; 2015.

    Google Scholar 

  10. 10.

    IARC. Some Traditional Herbal Medicines, Some Mycotoxins, Naphthalene and Styrene. In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 82. Lyon: IARC Press; 2002. p. 171–300.

  11. 11.

    Kensler TW, Roebuck BD, Wogan GN, Groopman JD. Aflatoxin: a 50-year odyssey of mechanistic and translational toxicology. Toxicol Sci. 2011;120(Suppl 1):S28–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Marasas WF. Fumonisins: history, world-wide occurrence and impact. Adv Exp Med Biol. 1996;392:1–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Shephard GS, Thiel PG, Stockenstrom S, Sydenham EW. Worldwide survey of fumonisin contamination of corn and corn-based products. J AOAC Int. 1996;79(3):671–87.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Etcheverry M, Nesci A, Barros G, Torres A, Chulze S. Occurrence of Aspergillus section Flavi and aflatoxin B1 in corn genotypes and corn meal in Argentina. Mycopathologia. 1999;147(1):37–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Abbas HK, Cartwright RD, Xie W, Thomas SW. Aflatoxin and fumonisin contamination of corn (maize, Zea mays) hybrids in Arkansas. Crop Prot. 2006;25(1):1–9.

    Article  CAS  Google Scholar 

  16. 16.

    Kumi J, Mitchell NJ, Asare GA, Dotse E, Kwaa F, Phillips TD, et al. Aflatoxins and fumonisins contamination of home-made food (weanimix) from cereal-legume blends for children. Ghana Med J. 2014;48(3):121–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Madbouly AK, Ibrahim MI, Sehab AF, Abdel-Wahhab MA. Co-occurrence of mycoflora, aflatoxins and fumonisins in maize and rice seeds from markets of different districts in Cairo, Egypt. Food Addit Contam Part B Surveill. 2012;5(2):112–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. 18.

    Rocha LO, Nakai VK, Braghini R, Reis TA, Kobashigawa E, Correa B. Mycoflora and co-occurrence of fumonisins and aflatoxins in freshly harvested corn in different regions of Brazil. Int J Mol Sci. 2009;10(11):5090–103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. 19.

    Sun G, Wang S, Hu X, Su J, Zhang Y, Xie Y, et al. Co-contamination of aflatoxin B-1 and fumonisin B-1 in food and human dietary exposure in three areas of China. Food Addit Contam A. 2011;28(4):461–70.

    Article  CAS  Google Scholar 

  20. 20.

    Torres O, Matute J, Waes JG-v, Maddox JR, Gregory SG, Ashley-Koch AE, et al. Human health implications from co-exposure to aflatoxins and fumonisins in maize-based foods in Latin America: Guatemala as a case study. World Mycotoxin J. 2015;8(2):143–59.

    Article  CAS  Google Scholar 

  21. 21.

    Yoshizawa T, Yamashita A, Chokethaworn N. Occurrence of fumonisins and aflatoxins in corn from Thailand. Food Addit Contam. 1996;13(2):163–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. 22.

    Wild CP, Gong YY. Mycotoxins and human disease: a largely ignored global health issue. Carcinogenesis. 2010;31(1):71–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. 23.

    Dutton MF. Fumonisins, mycotoxins of increasing importance: their nature and their effects. Pharmacol Ther. 1996;70(2):137–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. 24.

    Sun G, Wang S, Hu X, Su J, Huang T, Yu J, et al. Fumonisin B1 contamination of home-grown corn in high-risk areas for esophageal and liver cancer in China. Food Addit Contam. 2007;24(2):181–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. 25.

    Perera FP, Weinstein IB. Molecular epidemiology: recent advances and future directions. Carcinogenesis. 2000;21(3):517–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. 26.

    Sabbioni G, Ambs S, Wogan GN, Groopman JD. The aflatoxin-lysine adduct quantified by high-performance liquid chromatography from human serum albumin samples. Carcinogenesis. 1990;11(11):2063–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. 27.

    Cai Q, Tang L, Wang JS. Validation of fumonisin biomarkers in F344 rats. Toxicol Appl Pharmacol. 2007;225(1):28–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. 28.

    Riley RT, Torres O, Showker JL, Zitomer NC, Matute J, Voss KA, et al. The kinetics of urinary fumonisin B1 excretion in humans consuming maize-based diets. Mol Nutr Food Res. 2012;56(9):1445–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. 29.

    Shephard GS, Van Der Westhuizen L, Sewram V. Biomarkers of exposure to fumonisin mycotoxins: a review. Food Addit Contam. 2007;24(10):1196–201.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. 30.

    Torres O, Matute J, Gelineau-van Waes J, Maddox JR, Gregory SG, Ashley-Koch AE, et al. Urinary fumonisin B1 and estimated fumonisin intake in women from high- and low-exposure communities in Guatemala. Mol Nutr Food Res. 2014;58(5):973–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. 31.

    WHO. Fumonisin B1. Environmental Health Criteria 219. Geneva: World Health Organization; 2000. p. 1–134.

    Google Scholar 

  32. 32.

    Sydenham EW, Thiel PG, Marasas WFO, Shephard GS, Van Schalkwyk DJ, Koch KR. Natural occurrence of some Fusarium mycotoxins in corn from low and high esophageal cancer prevalence areas of the Transkei, southern Africa. J Agric Food Chem. 1990;38(10):1900–3.

    Article  CAS  Google Scholar 

  33. 33.

    Alizadeh AM, Roshandel G, Roudbarmohammadi S, Roudbary M, Sohanaki H, Ghiasian SA, et al. Fumonisin B1 contamination of cereals and risk of esophageal cancer in a high risk area in northeastern Iran. Asian Pac J Cancer Prev. 2012;13(6):2625–8.

    Article  Google Scholar 

  34. 34.

    Ueno Y, Iijima K, Wang S-D, Sugiura Y, Sekijima M, Tanaka T, et al. Fumonisins as a possible contributory risk factor for primary liver cancer: a 3-year study of corn harvested in Haimen, China, by HPLC and ELISA. Food Chem Toxicol. 1997;35(12):1143–50.

    Article  CAS  Google Scholar 

  35. 35.

    Li F-Q, Yoshizawa T, Kawamura O, Luo X-Y, Li Y-W. Aflatoxins and fumonisins in corn from the high-incidence area for human hepatocellular carcinoma in Guangxi, China. J Agric Food Chem. 2001;49(8):4122–6.

    Article  CAS  Google Scholar 

  36. 36.

    Qian G, Tang L, Lin S, Xue KS, Mitchell NJ, Su J, et al. Sequential dietary exposure to aflatoxin B1 and fumonisin B1 in F344 rats increases liver preneoplastic changes indicative of a synergistic interaction. Food Chem Toxicol. 2016;95:188–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. 37.

    Carlson DB, Williams DE, Spitsbergen JM, Ross PF, Bacon CW, Meredith FI, et al. Fumonisin B1 promotes aflatoxin B1 and N-methyl-N'-nitro-nitrosoguanidine-initiated liver tumors in rainbow trout. Toxicol Appl Pharmacol. 2001;172(1):29–36.

    Article  CAS  Google Scholar 

  38. 38.

    Gelderblom WC, Marasas WF, Lebepe-Mazur S, Swanevelder S, Vessey CJ, Hall PL. Interaction of fumonisin B(1) and aflatoxin B(1) in a short-term carcinogenesis model in rat liver. Toxicology. 2002;171(2–3):161–73.

    Article  CAS  Google Scholar 

  39. 39.

    Sabbioni G, Skipper PL, Buchi G, Tannenbaum SR. Isolation and characterization of the major serum albumin adduct formed by aflatoxin B1 in vivo in rats. Carcinogenesis. 1987;8(6):819–24.

    Article  CAS  Google Scholar 

  40. 40.

    Huang GL, Yang L, Su M, Wang SK, Yin H, Wang JS, et al. Vitamin D3 and beta-carotene deficiency is associated with risk of esophageal squamous cell carcinoma - results of a case-control study in China. Asian Pac J Cancer Prev. 2014;15(2):819–23.

    Article  PubMed  PubMed Central  Google Scholar 

  41. 41.

    Qian G, Tang L, Wang F, Guo X, Massey ME, Williams JH, et al. Physiologically based toxicokinetics of serum aflatoxin B1-lysine adduct in F344 rats. Toxicology. 2013;303:147–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. 42.

    Xu L, Cai Q, Tang L, Wang S, Hu X, Su J, et al. Evaluation of fumonisin biomarkers in a cross-sectional study with two high-risk populations in China. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2010;27(8):1161–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. 43.

    Andersson T, Alfredsson L, Kallberg H, Zdravkovic S, Ahlbom A. Calculating measures of biological interaction. Eur J Epidemiol. 2005;20(7):575–9.

    Article  PubMed  PubMed Central  Google Scholar 

  44. 44.

    Jaskiewicz K, Marasas WF, van der Walt FE. Oesophageal and other main cancer patterns in four districts of Transkei, 1981-1984. S Afr Med J. 1987;72(1):27–30.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. 45.

    Rheeder J, Marasas W, Thiel P, Sydenham E, Shephard G, Van Schalkwyk D. Fusarium moniliforme and fumonisins in corn in relation to human esophageal cancer in Transkei. Phytopathology. 1992;82(3):353–7.

    Article  Google Scholar 

  46. 46.

    Shephard GS, Marasas WF, Burger HM, Somdyala NI, Rheeder JP, Van der Westhuizen L, et al. Exposure assessment for fumonisins in the former Transkei region of South Africa. Food Addit Contam. 2007;24(6):621–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. 47.

    Shephard GS, van der Westhuizen L, Gatyeni PM, Somdyala NI, Burger HM, Marasas WF. Fumonisin mycotoxins in traditional Xhosa maize beer in South Africa. J Agric Food Chem. 2005;53(24):9634–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. 48.

    van der Westhuizen L, Shephard GS, Rheeder JP, Burger HM. Individual fumonisin exposure and sphingoid base levels in rural populations consuming maize in South Africa. Food Chem Toxicol. 2010;48(6):1698–703.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. 49.

    van der Westhuizen L, Shephard GS, Rheeder JP, Somdyala NI, Marasas WF. Sphingoid base levels in humans consuming fumonisin-contaminated maize in rural areas of the former Transkei, South Africa: a cross-sectional study. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2008;25(11):1385–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. 50.

    Gong HZ, Ji R, Li YX, Zhang HY, Li B, Zhao Y, et al. Occurrence of fumonisin B(1) in corn from the main corn-producing areas of China. Mycopathologia. 2009;167(1):31–6.

    Article  PubMed  PubMed Central  Google Scholar 

  51. 51.

    Abnet CC, Borkowf CB, Qiao YL, Albert PS, Wang E, Merrill AH Jr, et al. Sphingolipids as biomarkers of fumonisin exposure and risk of esophageal squamous cell carcinoma in China. Cancer Causes Control. 2001;12(9):821–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. 52.

    Ghasemi-Kebria F, Joshaghani H, Taheri NS, Semnani S, Aarabi M, Salamat F, et al. Aflatoxin contamination of wheat flour and the risk of esophageal cancer in a high risk area in Iran. Cancer Epidemiol. 2013;37(3):290–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. 53.

    Vleet TRV, Klein PJ, Jr RAC. Metabolism and cytotoxicity of aflatoxin B 1 in cytochrome P-450-expressing human lung cells. J Toxic Environ Health A. 2002;65(12):853–67.

    Article  Google Scholar 

  54. 54.

    Carvajal-Moreno M. Do gastroenterologists consider aflatoxins as origin of digestive system cancers. J Pharmacovigil. 2017;5:242.

    Article  CAS  Google Scholar 

  55. 55.

    Li Z, Cui J, Zhang X, Kang W. Aflatoxin G 1 reduces the molecular expression of HLA-I, TAP-1 and LMP-2 of adult esophageal epithelial cells in vitro. Toxicol Lett. 2010;195(2):169–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. 56.

    Shirima CP, Kimanya ME, Kinabo JL, Routledge MN, Srey C, Wild CP, et al. Dietary exposure to aflatoxin and fumonisin among Tanzanian children as determined using biomarkers of exposure. Mol Nutr Food Res. 2013;57(10):1874–81.

    CAS  PubMed  PubMed Central  Google Scholar 

  57. 57.

    Shirima CP, Kimanya ME, Routledge MN, Srey C, Kinabo JL, Humpf HU, et al. A prospective study of growth and biomarkers of exposure to aflatoxin and fumonisin during early childhood in Tanzania. Environ Health Perspect. 2015;123(2):173–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. 58.

    Clarke R, Connolly L, Frizzell C, Elliott CT. Cytotoxic assessment of the regulated, co-existing mycotoxins aflatoxin B1, fumonisin B1 and ochratoxin, in single, binary and tertiary mixtures. Toxicon. 2014;90:70–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. 59.

    McKean C, Tang L, Tang M, Billam M, Wang Z, Theodorakis CW, et al. Comparative acute and combinative toxicity of aflatoxin B1 and fumonisin B1 in animals and human cells. Food Chem Toxicol. 2006;44(6):868–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. 60.

    Riley RT, Torres O, Matute J, Gregory SG, Ashley-Koch AE, Showker JL, et al. Evidence for fumonisin inhibition of ceramide synthase in humans consuming maize-based foods and living in high exposure communities in Guatemala. Mol Nutr Food Res. 2015;59(11):2209–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. 61.

    Tessari EN, Oliveira CA, Cardoso AL, Ledoux DR, Rottinghaus GE. Effects of aflatoxin B1 and fumonisin B1 on body weight, antibody titres and histology of broiler chicks. Br Poult Sci. 2006;47(3):357–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. 62.

    Xu L, Qian G, Tang L, Su J, Wang JS. Genetic variations of hepatitis B virus and serum aflatoxin-lysine adduct on high risk of hepatocellular carcinoma in southern Guangxi, China. J Hepatol. 2010;53(4):671–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. 63.

    Wang JS, Huang T, Su J, Liang F, Wei Z, Liang Y, et al. Hepatocellular carcinoma and aflatoxin exposure in Zhuqing Village, Fusui County, People’s Republic of China. Cancer Epidemiol Biomarkers Prev. 2001;10(2):143–6.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Field study team members from Huaian Center for Disease Control and Prevention and voluntary study participants who provided their blood and urine samples are greatly appreciated.

Funding

This study was supported by grants CA94683 (for field study including in the design of the study and data collection) and CA90997 (for laboratory analysis including biomarker analysis and interpretation of data) from National Cancer Institute/National Institutes of Health to Dr. Jia-Sheng Wang. The manuscript writing and publication cost are supported by the University of Georgia.

Author information

Affiliations

Authors

Contributions

KX participated in biomarkers analyses and the writing of manuscript. LT participated in study design, performed biomarkers measurements, as well as statistical analyses. GS, SW, and XH participated in study design, and participated in collection of field samples and questionnaires, as well as coordination of the field studies. JSW participated in study design and act as the principal investigator for the entire project, whom supervises various stages of the study. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Jia-Sheng Wang.

Ethics declarations

Ethics approval and consent to participate

The study protocols including ethics guidelines and bilingual consent forms (English and Chinese) were approved by the Institutional Review Boards for human subjects at Southeast University School of Public Health and Texas Tech University (human subject assurance number: 00001568) and was compliant with human research ethics guidelines of the respective institutions. Written consents were obtained from all participants in the study.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Xue, K.S., Tang, L., Sun, G. et al. Mycotoxin exposure is associated with increased risk of esophageal squamous cell carcinoma in Huaian area, China. BMC Cancer 19, 1218 (2019). https://doi.org/10.1186/s12885-019-6439-x

Download citation

Keywords

  • Aflatoxin B1
  • Co-exposure
  • Fumonisin B1
  • Esophageal cancer
  • Molecular epidemiology
  • Mycotoxins